"The Cochrane Collaboration concluded that while the approach does slow Alzheimer's disease, it does not do so by enough to make a meaningful difference to patients."
"Prof Edo Richard stated, 'I would tell them, I think you will probably not benefit from these drugs and they're burdensome for you and your family.'"
"The drugs target beta amyloid, a sticky substance that accumulates in the brain, but come with risks and require frequent administration."
Recent analysis indicates that breakthrough Alzheimer's drugs, while capable of slowing cognitive decline, do not provide meaningful benefits to patients. The NHS currently does not cover these drugs, which are expensive and may pose risks such as brain swelling and bleeding. Trials of drugs like donanemab and lecanemab showed some promise, but the overall impact was deemed insufficient. Experts emphasize the burden these treatments may impose on patients and their families, questioning their value despite the high costs involved.
Read at www.bbc.com
Unable to calculate read time
Collection
[
|
...
]